title: Current Treatment Strategies for Heart Failure: Role of Device Therapy and LV Reconstruction.
abstract: Medical care of heart failure (HF) begins with the determination of the cause of the heart failure and diagnosing potential reversible causes (i.e., coronary heart disease, hyperthyroidism, etc.). Medical therapy includes pharmacological and nonpharmacological strategies that limit and/or reverse the signs and symptoms of HF. Initial behavior modification includes dietary sodium and fluid restriction to avoid weight gain; and encouraging physical activity when appropriate. Optimization of medical therapy is the first line of treatment that includes the use of diuretics, vasodilators (i.e., ACE inhibitors or ARBs), beta blockers, and potentially inotropic agents and anticoagulation depending on the patient's severity of heart failure and LV dysfunction. As heart failure advances despite optimized medical management, cardiac resynchronization therapy (CRT), and implantable cardioverter defibrillators (ICDs) are appropriate device therapies. The development of progressive end-stage HF, despite maximal medical therapy, necessitates the consideration of mechanical circulatory devices such as ventricular assist devices (VADs) either as a bridge to heart transplantation or as destination therapy. Despite the advances in the treatment of heart failure, there is still a large morbidity and mortality associated with HF, thus the need to develop newer strategies for the treatment of HF.
authors.affiliation: Department of Medicine, University of California San Francisco, San Francisco, CA, USA.
authors.forename: Praneeth
authors.initials: P
authors.lastname: Janaswamy
authors.affiliation: Department of Medicine, University of California San Francisco, San Francisco, CA, USA.
authors.forename: Tomos E
authors.initials: TE
authors.lastname: Walters
authors.affiliation: Department of Medicine, University of California San Francisco, San Francisco, CA, USA.
authors.forename: Babak
authors.initials: B
authors.lastname: Nazer
authors.affiliation: Department of Medicine, University of California San Francisco, San Francisco, CA, USA. lee@medicine.ucsf.edu.|Cardiovascular Research Institute, University of California San Francisco, San Francisco, CA, USA. lee@medicine.ucsf.edu.|Institute for Regeneration Medicine, University of California San Francisco, San Francisco, CA, USA. lee@medicine.ucsf.edu.|University of California San Francisco, Box 1354, San Francisco, CA, 94143, USA. lee@medicine.ucsf.edu.
authors.forename: Randall J
authors.initials: RJ
authors.lastname: Lee
keywords: Cardiac resynchronization therapy; Heart failure; ICD; Tissue engineering